ViCardia Therapeutics
San Francisco, US · Delaware corporation
Find your way into ViCardia Therapeutics
Sign up to see every warm intro you have to ViCardia Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ViCardia Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$700K disclosed across 1 round · 2026
▶$700KraisedMay 2026 · 1 investors · BiotechnologyRule 506(b)
▶$700KraisedMay 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KokeshExecutive Officer
- Offering amount
- $700K
- Amount sold
- $700K
- Minimum investment
- $10K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has ViCardia Therapeutics raised?
- ViCardia Therapeutics has disclosed $700K raised across 1 round.
- Where is ViCardia Therapeutics headquartered?
- ViCardia Therapeutics is headquartered in San Francisco, US.
